Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sutent
Sunitinib is a small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis. It works by blocking the signaling pathways of these RTKs, thereby inhibiting cell proliferation, survival, and the formation of new blood vessels that supply tumors. Sunitinib is primarily used in the treatment of certain types of cancer.
For the treatment of gastrointestinal stromal tumor (GIST), renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (pNET).
Sunitinib can cause severe and potentially fatal liver problems, heart failure, high blood pressure, QT interval prolongation, bleeding problems, reversible posterior leukoencephalopathy syndrome (RPLS), thrombotic microangiopathy (TMA), thyroid problems, and impaired wound healing. It can also cause fetal harm.
Outcome:
Increased risk of bleeding
Mechanism:
Sunitinib can inhibit CYP2C9, increasing warfarin levels.
Outcome:
Increased risk of hypertension and bleeding
Mechanism:
Additive antiangiogenic effects.
Outcome:
Potential for hepatotoxicity
Mechanism:
Additive effects on the liver.
Most likely new formulation: Controlled-release formulation (Year 2026, 60% confidence)
Based on current usage trends and clinical trial outcomes, there is a 70% likelihood of sunitinib maintaining its current indications and approval status for the next 5 years.
Tyrosine Kinase Inhibitor, Antineoplastic Agent
Indolinone